Given the capability of FASN to impair HSV-1 infectivity, we reasoned that targeting lipid metabolism may constitute an innovative approach to reduce the risk of virus reactivation, an especially critical concern in the context of neurodegenerative diseases, such as Alzheimer’s disease (AD). Here, FASN is linked to neurodegenerative disease.